

NOTICE TO CONVENE THE ANNUAL GENERAL MEETING

DANSK BIOTEK
(CVR no. 28 43 65 72)

Notice is hereby given to the Annual General Meeting of DANSK BIOTEK to be held on

Friday, 6 May 2022, at 14:00 (CEST)
at Børsen, Slotsholmsgade, DK-1216 Copenhagen

The agenda is as follows:

- a) Election of Chairman of the Annual General Meeting
- b) Chairman's statement
- c) Approval of financial result for 2021
- d) Determination of membership fee for 2022
- e) Election of Chairman
- f) Election of Members of the Board
- g) Election of Board Observers
- h) Election of Auditor
- i) Proposal from the Board to determine the membership fees for 2023
- j) Proposal from the Board to amend the Articles of Association of DANSK BIOTEK
 - 1. Amendment of name (§ 1)
 - 2. Amendment of § 6(c) regarding determination of membership fee
- k) Discussion of proposals
- l) Any other business

Re a) - Election of chairman of the Annual General Meeting

The Board proposes election of Attorney-at-Law, Thomas Holst Laursen as Chairman of the Annual General Meeting.

Re b) - Chairman's statement

Chairman Hans Schambye makes his statement regarding the previous year.

Re c) - Approval of financial result for 2021

The Board proposes that the Annual Report with the auditor's report for 2021 is approved.

Re d) - Determination of membership fee for 2022

The Board proposes that the membership fee for 2022 shall be unchanged compared to 2021.

Re e) - Election of Chairman

The Chairman is elected for a two-year period and may be re-elected. Hans Schambye continues as Chairman of the Board (2021-2023).

Re f) - Election of Members of the Board

The Board is elected for a two-year period and may be re-elected.

The Board proposes re-election of the following board members, who stand for election:

- Adam Steensberg, Executive Vice President, Zealand Pharma (2022-2024)
- Mai-Britt Zocca, CEO & founder, IO Biotech ApS (2022-2024)

Further, the Board proposes election of the following new board member:

- Thomas Kongstad Petersen, Chief Operating Officer, NMD Pharma (2022-2024)

The following member does not stand for re-election:

- Anders Hinsby, CEO, Muna Therapeutics (2019-2021)

The following board members continue:

- Hans Schambye, CEO, Galecto Inc. (Chairman) (2021-2023)
- Alejandra Mørk, CEO, KLIFO A/S (2021-2023)
- Henrik Blou, CEO, Gubra (2021-2023)
- Lone Dybdal Nilsson, Vice President, Applied Research Agriculture & Industrial Biosolutions, Novozymes North America Inc. (2021-2023)
- Søren Møller, Managing Partner, Novo Holdings A/S (2021-2023)

Re g) - Election of Board Observer

The Board proposes election of the following new board observer:

- Jørgen Godt Olsen, Executive Vice President, NCK A/S (2022-2024)

Re h) - Election of Auditor

The Board proposes re-election of EY Godkendt Revisionspartnerselskab, CVR no. 30 70 02 28, as the auditor of DANSK BIOTEK.

Re i) - Determination of membership fees for 2023

The Board proposes that the General Meeting shall determine the membership fees for 2023, which are proposed amended compared to 2022.

The past couple of years have meant massive changes for everyone, not least all who work in the life science sector. The clear demonstration that biotech companies provided the solutions to the covid pandemic – both vaccines, treatments, and tests – have resulted in massively increased understanding of our sector among Danish politicians. DANSK BIOTEK has worked hard to leverage this increased attention, and make sure to let our voice be heard in the development of political initiatives, such as the Life Science Strategy. For instance DANSK BIOTEK

has pushed hard to make access to scientific literature easier for biotech companies, and we are also very happy to see that a new attempt at removing the dreaded Phantom Tax is making its way through Folketinget.

The increased activities on DANSK BIOTEK's side have made it clear that we need to strengthen our human resource muscles in order to make sure that the interest of Danish biotech companies is taken better care of. It is not least important that we have the manpower to work better together with other organizations such as Lif, Dansk Erhverv, Dansk Industri and Medicindustrien. The board of DANSK BIOTEK is therefore proposing that we revise our membership fees so we have the means to hire staff that can help the board and liaise with other parties. We have studied the fees of similar organizations, such as MVA and Sweden BIO and can see that our current fees are 50% or less of the fees of our peers. Hence, the Board proposes that our members at the upcoming AGM adopt the proposal to modify fees as follows:

Member type	Current fee – DKK	New proposal – DKK	MVA fee as comparison - DKK
Biotech – <10 employees	4000	5000	7500 – 11000
Biotech – 10 - 200 employees	10000	15000	11000 – 77500
Biotech – 200 - 1000 employees	20000	35000	77500 – 357500
Biotech – >1000 employees	30000	50000	>357500
Associated company - <10 employees	10000	15000	7500 – 11000
Associated company – 10 - 200 employees	10000	20000	11000 – 77500
Associated company – > 200 employees	10000	40000	>77500

Re j) Proposal from the Board to amend the Articles of Association of DANSK BIOTEK

Re item j)(1):

The Board proposes that we align our new, more international style with our name – hence, we propose that our official name is changed to DANISH BIO - DANSK BIOTEK.

Specifically, it is proposed to amend § 1 as follows (English and Danish):

"§ 1 Name

The name of the Association is DANISH BIO - DANSK BIOTEK – with the alias Foreningen af Bioteknologiske Industrier i Danmark."

"§ 1 Navn

Foreningens navn er DANISH BIO - DANSK BIOTEK — med binavnet Foreningen af Bioteknologiske Industrier i Danmark."

Re item j)(2):

The Board proposes that § 6(c) of the Articles of Association shall be amended so that the membership fees of DANSK BIOTEK will be determined for the following calendar year (instead of the current calendar year).

The current § 6 will thus be amended as follows (English and Danish):

"§ 6 Agenda

[...]

c) Fastsættelse af kontingent for det følgende kalenderår.

[...]"

"§ 6 Dagsorden

[...]

c) Determination of membership fee for the following calendar year.

[...]"

- 0 -

The approved Articles of Association will be available on DANSK BIOTEK's website after the Annual General Meeting.

Re k) - Discussion of proposals

No proposals have been received.

Re l) - Any other business

Any other business.

- 0 -

Resolution requirements

The proposals set out in items a)-i) of the agenda must be adopted by a simple majority of votes. Adoption of the proposals set out in item j) of the agenda requires at least 3/4 majority of the members of DANSK BIOTEK.

Practical information

To ensure a smooth course of events at the Annual General Meeting, we encourage the Members to give proxy to the Chairman of the Board to vote on their behalf at the Annual General Meeting (power of attorney is attached to this notice). A scanned copy of the completed and signed power of attorney must be sent by e-mail to: dd@danskbiotek.dk no later than on Wednesday, 5 May 2021, at 10:00 (CEST).

Further, we encourage the Members to submit any questions well in advance of the Annual General Meeting.

- 0 -

Date: 6 May 2022

Kind regards

The Board of DANSK BIOTEK